Scholarlink

<p>Urease inhibition, a nickel-containing metalloenzyme, is a promising approach for treating Helicobacter pylori (H. pylori) infections as a critical virulence factor that allows the bacteria to colonize the gastric mucosa and survive the acidic environment of the stomach. In this context, we report the design, synthesis, in vitro evaluation, and molecular dynamics simulation (MD) studies of novel ((4,7-dimethyl-2-oxo-2<i>H</i>-chromen-5-yl)oxy)acetohydrazide derivatives as urease enzyme inhibitors. Notably, all compounds exhibited potent inhibitory activities, with IC<sub>50</sub> values ranging from 2.438 µM to 4.427 µM. Further kinetic studies revealed that compound <b>11g</b> as the most potent compound with IC<sub>50</sub> value of 2.438 ± 0.31 μM acts as a non-competitive inhibitor toward urease with an inhibition constant (Ki) of 2.33 μM. In silico studies elucidated the binding interactions of compound <b>11g</b>, revealing crucial hydrogen bonds with key amino acid residues as well as chelation with Ni ions within the active site of urease. Molecular dynamics (MD) simulations confirmed the stable ligand-urease complex maintains interactions with both the active site residues and the flap moiety of urease, acting as noncompetitive inhibitors. These findings demonstrate the potential of coumarin-acetohydrazide Schiff base derivatives as a new frontier in developing urease inhibitors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Design, synthesis, in vitro evaluation, and molecular dynamics simulation studies of novel coumarin-acetohydrazide Schiff base derivatives as urease enzyme inhibitors

  • 期刊论文

  • 发表日期：

    2025年1月13日

查看全文
  • Mohammad Azimi,
  • Hassan Sepehrmansourie,
  • Ahmad Ebadi,
  • Gholamabbas Chehardoli,
  • Mohammad Ali Zolfigol,
  • Massoud Amanlou,
  • Mohammad Nazari Montazer,
  • Mohammad Mahdavi,
  • Zahra Najafi

摘要

Urease inhibition, a nickel-containing metalloenzyme, is a promising approach for treating Helicobacter pylori (H. pylori) infections as a critical virulence factor that allows the bacteria to colonize the gastric mucosa and survive the acidic environment of the stomach. In this context, we report the design, synthesis, in vitro evaluation, and molecular dynamics simulation (MD) studies of novel ((4,7-dimethyl-2-oxo-2H-chromen-5-yl)oxy)acetohydrazide derivatives as urease enzyme inhibitors. Notably, all compounds exhibited potent inhibitory activities, with IC50 values ranging from 2.438 µM to 4.427 µM. Further kinetic studies revealed that compound 11g as the most potent compound with IC50 value of 2.438 ± 0.31 μM acts as a non-competitive inhibitor toward urease with an inhibition constant (Ki) of 2.33 μM. In silico studies elucidated the binding interactions of compound 11g, revealing crucial hydrogen bonds with key amino acid residues as well as chelation with Ni ions within the active site of urease. Molecular dynamics (MD) simulations confirmed the stable ligand-urease complex maintains interactions with both the active site residues and the flap moiety of urease, acting as noncompetitive inhibitors. These findings demonstrate the potential of coumarin-acetohydrazide Schiff base derivatives as a new frontier in developing urease inhibitors.